Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy

Bender, Bruce G.; Vecino, Ramon A. Hernandez; McGrath, Kevin; Jones, Spencer

doi:10.1016/j.jaip.2016.07.006

Cited by 13 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Persistence is therefore also an important indication of patients’ long-term behavior impacting clinical outcome. Factors associated with poor persistence in patients may include lack of symptoms, confusion around medications, and difficulty in handling the inhaler device 20. Among other factors, level of patient knowledge/education, inhaler convenience and satisfaction, age, adverse effects and medication costs may influence nonadherence in patients with COPD 21…”

Section: Introductionmentioning

confidence: 99%

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population

Bogart¹,

Stanford²,

Laliberté³

et al. 2019

COPD

View full text Add to dashboard Cite

Introduction This longitudinal, retrospective cohort study of patients with COPD describes baseline characteristics, adherence, and persistence following initiation of inhaled corticosteroids (ICS)/long-acting β 2 -agonists (LABA)/long-acting muscarinic antagonists (LAMA) from multiple inhaler triple therapy (MITT). Methods Patients aged ≥40 years receiving MITT between January 2012 and September 2015 were identified from the IQVIA™ Real-world Data Adjudicated Claims–USA database. MITT was defined as subjects with ≥1 overlapping days’ supply of three COPD medications (ICS, LABA, and LAMA). Adherence (proportion of days covered, PDC) and discontinuation (defined as a gap of 1, 30, 60, or 90 days of supply in any of the three components of the triple therapy) were calculated for each patient over 12 months of follow-up. In addition, analyses were stratified by number of inhalers. Results In total, 14,635 MITT users were identified (mean age, 62 years). Mean PDC for MITT at 12 months was 0.37%. Mean PDC for the ICS/LABA and LAMA component at 12 months was 49% (0.49±0.31; median, 0.47) and 54% (0.54±0.33; 0.56), respectively. The proportion of adherent patients (PDC ≥0.8) at 12 months was 14% for MITT. Allowing for a 30-day gap from last day of therapy, 86% of MITT users discontinued therapy during follow-up. Conclusion Patients with COPD had low adherence to and persistence with MITT in a real-world setting. Mean PDC for each single inhaler component was higher than the mean PDC observed with MITT. Reducing the number of inhalers may improve overall adherence to intended triple therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population

Bogart¹,

Stanford²,

Laliberté³

et al. 2019

COPD

View full text Add to dashboard Cite

show abstract

“…Although effective COPD treatments are available, observational studies have shown varying results regarding the association of treatment adherence or persistence with exacerbations and healthcare resource use (HRU) 8–12. While persistence is defined as the absence of critical gaps in treatment (ie continuation of therapy), adherence is defined as the regular intake of a drug (implementation) 13–17. A good understanding of the level of COPD treatment persistence in patients could help optimize disease management and quality of care.…”

Section: Introductionmentioning

confidence: 99%

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy

Dalon¹,

Devouassoux

Belhassen

et al. 2019

COPD

View full text Add to dashboard Cite

PurposeThis study assessed therapy persistence in patients with chronic obstructive pulmonary disease (COPD) in France, and the impact of non-persistence on exacerbations and described COPD-related healthcare resource use (HRU).MethodsPatients aged ≥45 years who received ≥1 dispensed bronchodilator per quarter over three consecutive quarters between 2007 and 2014 and initiated specific COPD therapy were selected from the Echantillon Généraliste des Bénéficiaires (EGB) database. Persistence, defined as the absence of dispensing gaps of >90 days, was measured at 12 months. Exacerbations were compared between persistent and non-persistent patients during follow-up after patient matching and adjustment for confounding factors. COPD-related HRU during follow-up was described.ResultsAmong 4020 patients with COPD, 2164 initiated a specific therapy. Of these, 54.4% stopped treatment within 12 months. Persistence with all COPD therapy regimens was low, particularly for inhaled corticosteroid (ICS; 25.6%) and ICS/twice-daily long-acting beta-agonist (39.4%) regimens. Among 721 persistent patients who were matched with 721 non-persistent patients, there was no difference in the number of moderate or severe exacerbations at 12 months. However, medical procedures (for instance, pulmonary function testing and chest X-rays) were more frequently observed among persistent patients than among non-persistent patients, suggesting worse disease severity.ConclusionPatients receiving specific treatment(s) for COPD demonstrated low persistence for all examined therapy regimens, with no clear impact of persistence status on the frequency of exacerbations at 12 months.

show abstract

“…Real-world data provide valuable information on the effectiveness of treatment in a much wider patient population than would be evaluated in a Phase III clinical trial program. Persistence to treatment with fluticasone propionate/salmeterol via the Forspiro device relative to another dry powder inhaler (Seretide ® Diskus ® ; GlaxoSmithKline, Brentford, UK) has already been assessed in a large retrospective analysis of a pharmacy database, which showed greater persistence with the Forspiro device in patients with asthma and chronic obstructive pulmonary disease (COPD) 14. The noninterventional study ASSURE was designed primarily to assess patients’ asthma control and quality of life while using the Forspiro inhaler device in everyday practice, for the treatment of bronchial asthma in line with its licensed indication.…”

Section: Introductionmentioning

confidence: 99%

A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patients’ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)

Backer

Bjermer

Refvem³

et al. 2019

POR

Self Cite

View full text Add to dashboard Cite

Background: The design of inhaler devices may potentially influence adherence/persistence and outcomes in asthma. Objective: The primary objective was to assess asthma control and any change in the quality of life in patients using an intuitive dry powder inhaler containing fluticasone propionate/salmeterol (AirFluSal ® Forspiro ® ) for the treatment of asthma in everyday practice. Methods: ASSURE was a multicenter, noninterventional, open-label, prospective study in patients with asthma, aged ≥12 years and treated with the Forspiro device in Denmark, Sweden and Norway. Patients’ opinions of their asthma control were assessed by the Asthma Control Test (ACT) questionnaire and asthma-related quality of life by the Mini Asthma Quality of Life Questionnaire (miniAQLQ) at baseline and at two follow-up visits (approximately 4–8-week intervals). Results: Of 321 patients enrolled in the study, 299 received at least one dose of fluticasone propionate/salmeterol via the Forspiro device and 204 had evaluable data at the baseline visit and at least one later visit. Patients showed improvements in asthma control and quality of life during the study. The mean sum score of ACT increased from 18.0 (SD 4.5) at visit 1 to 19.9 (4.2) at visit 2 and 20.5 (4.3) at visit 3. Overall, 38.2% of patients improved by the minimal clinically important difference (MCID) of ≥3 points (45.6% among those with a baseline score below 23 [ie, not already well controlled]). The mean score on the miniAQLQ increased from 5.16 (SD 1.24) at visit 1 to 5.58 (SD 1.20) at visit 2 and 5.82 (SD 1.04) at visit 3. Overall, 42.6% of patients improved by the MCID of ≥0.5. Conclusion: This real-life study suggests that treatment with fluticasone propionate/salmeterol via the Forspiro device can improve asthma symptom control and quality of life.

show abstract

Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy

Cited by 13 publications

References 22 publications

<p>Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population</p>

<p>Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population</p>

<p>Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy</p>

<p>A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patients’ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)</p>

Contact Info

Product

Resources

About